CTMX
Cytomx Therapeutics Inc
NASDAQ · Biotechnology
$5.67
+0.43 (+8.21%)
Open$5.30
Previous Close$5.24
Day High$5.78
Day Low$5.30
52W High$6.35
52W Low$0.40
Volume—
Avg Volume3.34M
Market Cap960.70M
P/E Ratio34.29
EPS$0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,011.8% upside
Current
$5.67
$5.67
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 276.11M | 178.48M | 143.04M |
| Net Income | 63.72M | 37.07M | 18.37M |
| Profit Margin | 23.1% | 21.9% | 12.9% |
| EBITDA | 53.13M | 32.63M | 25.12M |
| Free Cash Flow | — | — | 17.80M |
| Rev Growth | +54.7% | +54.7% | -6.3% |
| Debt/Equity | — | — | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |